Director · Xeris Biopharma Holdings, Inc. · Xeris Biopharma Holdings, Inc. — Stock Option (Right to Buy)
Side
A
Value
$203K
Shares
33.0K
Price
$6.15
Executed
Jun 4, 2026
Disclosed
Jun 5, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jun 4 executedJun 5, 2026 disclosed
XERS · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+4 / 25
$203K reported value · new position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Xeris Biopharma Holdings, Inc. — Stock Option (Right to Buy)
Ticker
XERS
Shares
33.0K
Price per share
$6.15
Value
$202,925
Execution date (reported)
Jun 4, 2026
Owned after transaction
33.0K shares
Rule 10b5-1 plan
Yes, as checked by the filer
Days from execution to publication
1
Calculation
Value = shares × reported price per share
Shares: 33.0K
Price: $6.15
= $202,925
What this establishes
Persky Marla filed this Form 4 reporting a grant or award of XERS on Jun 4, 2026. It became public on Jun 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Persky Marlacik:0001270354
Issuer
Xeris Biopharma Holdings, Inc.cik:0001867096
Revision history · 0
No field has changed since this record was first ingested.
